| 产品编号 | bs-55166R |
| 英文名称 | [KO验证抗体] PDCD4 |
| 中文名称 | 凋亡相关蛋白4抗体 |
| 别 名 | PDCD-4; PDCD 4; Death up-regulated gene protein; Dug; H731; Ma3; MGC33046; MGC33047; Neoplastic transformation inhibitor; Neoplastic transformation inhibitor protein; Nuclear antigen H731; Nuclear antigen H731 like; Nuclear antigen H731 like protein; PDCD 4; Programmed cell death 4; programmed cell death 4 (neoplastic transformation inhibitor); Programmed cell death protein 4; Protein 197/15a; Protein MA-3; RP11 348N5.4; Tis; Nuclear antigen H731-like; Pdcd4; PDCD4_HUMAN; Topoisomerase-inhibitor suppressed protein; Topoisomerase-inhibitor suppressed protein (programmed cell death 4). |
| 研究领域 | 肿瘤 细胞生物 染色质和核信号 表观遗传学 |
| 抗体来源 | Rabbit |
| 克隆类型 | Polyclonal |
| 交叉反应 | Human (predicted: Mouse) |
| 产品应用 | WB=1:500-2000, IHC-P=1:400-800
not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
| 理论分子量 | 51kDa |
| 细胞定位 | 细胞核 细胞浆 |
| 性 状 | Liquid |
| 浓 度 | 1mg/ml |
| 免 疫 原 | Recombinant human PDCD4: 1-260/469 |
| 亚 型 | IgG |
| 纯化方法 | affinity purified by Protein A |
| 缓 冲 液 | 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
| 保存条件 | Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C. |
| 注意事项 | This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. |
| PubMed | PubMed |
| 产品介绍 |
This gene encodes a protein localized to the nucleus in proliferating cells. Expression of this gene is modulated by cytokines in natural killer and T cells. The gene product is thought to play a role in apoptosis but the specific role has not yet been determined. Two transcripts encoding different isoforms have been identified. Alternative names: H731; MGC33046; MGC33047; Neoplastic transformation inhibitor; Neoplastic transformation inhibitor protein; Nuclear antigen H731; Nuclear antigen H731 like; Nuclear antigen H731 like protein; OTTHUMP00000020483; PDCD 4; Programmed cell death 4; programmed cell death 4 (neoplastic transformation inhibitor) ; Programmed cell death protein 4; Protein 197/15a ; RP11 348N5.4 . Function: Inhibits translation initiation and cap-dependent translation. May excert its function by hindering the interaction between EIF4A1 and EIF4G. Inhibits the helicase activity of EIF4A. Modulates the activation of JUN kinase. Down-regulates the expression of MAP4K1, thus inhibiting events important in driving invasion, namely, MAPK85 activation and consequent JUN-dependent transcription. May play a role in apoptosis. Tumor suppressor. Inhibits tumor promoter-induced neoplastic transformation. Binds RNA (By similarity). Subunit: Interacts (via MI domains) with EIF4A2 (By similarity). Interacts (via MI domains) with EIF4A1 (via N-terminal domain). Heterotrimer with EIF4A1; one molecule of PDCD4 binds two molecules of EIF4A1. Interacts with EIF4G1. May form a complex with EIF4A1 and EIF4G1. The interaction between PDCD4 and EIF4A1 interferes with the interaction between EIF4A1 and EIF4G. When phosphorylated, interacts with BTRC and FBXW11. Subcellular Location: Nucleus. Cytoplasm. Note=Shuttles between the nucleus and cytoplasm. Predominantly nuclear under normal growth conditions, and when phosphorylated at Ser-457. Exported from the nucleus in the absence of serum. Tissue Specificity: Up-regulated in proliferative cells. Highly expressed in epithelial cells of the mammary gland. Reduced expression in lung cancer and colon carcinoma. Post-translational modifications: Polyubiquitinated, leading to its proteasomal degradation. Rapidly degraded in response to mitogens. Phosphorylation of the phosphodegron promotes interaction with BTRC and proteasomal degradation. Phosphorylated at Ser-67 by RPS6KB1 in response to mitogens; phosphorylation promotes proteasomal degradation of PDCD4. Similarity: Belongs to the PDCD4 family. Contains 2 MI domains. SWISS: Q53EL6 Gene ID: 27250 Database links: Entrez Gene: 27250 Human Entrez Gene: 18569 Mouse Omim: 608610 Human SwissProt: Q53EL6 Human SwissProt: Q61823 Mouse Unigene: 711490 Human Unigene: 1605 Mouse Unigene: 375091 Mouse Unigene: 206228 Rat 程序性细胞死亡因子4是近期发现一种新的抑癌基因，在很多肿瘤组织中有不同的表达。 |
| 产品图片 |
Sample:
Lane 1: Hela (Human) Cell Lysate at 25 ug Lane 2: PDCD4 knockout (KO) Hela (Human) Cell Lysate at 25 ug Primary: Anti-PDCD4 (bs-55166R) at 1/1000 dilution Secondary: HRP Goat Anti-Rabbit IgG (H+L) at 1:10000 dilution Predicted band size: 60 kD Observed band size: 60 kD 
Sample:
Lane 1: Hela (Human) Cell Lysate at 30 ug Lane 2: 293T (Human) Cell Lysate at 30 ug Lane 3: MCF-7 (Human) Cell Lysate at 30 ug Lane 4: HepG2 (Human) Cell Lysate at 30 ug Primary: Anti-PDCD4 (bs-55166R) at 1/1000 dilution Secondary: IRDye800CW Goat Anti-Rabbit IgG at 1/20000 dilution Predicted band size: 60 kD Observed band size: 58 kD 
Paraformaldehyde-fixed, paraffin embedded (human placenta); Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15min; Block endogenous peroxidase by 3% hydrogen peroxide for 20 minutes; Blocking buffer (normal goat serum) at 37°C for 30min; Antibody incubation with (PDCD4) Polyclonal Antibody, Unconjugated (bs-55166R) at 1:25 overnight at 4°C, followed by operating according to SP Kit(Rabbit) (sp-0023) instructionsand DAB staining.
Paraformaldehyde-fixed, paraffin embedded (human thyroid cancer); Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15min; Block endogenous peroxidase by 3% hydrogen peroxide for 20 minutes; Blocking buffer (normal goat serum) at 37°C for 30min; Antibody incubation with (PDCD4) Polyclonal Antibody, Unconjugated (bs-55166R) at 1:25 overnight at 4°C, followed by operating according to SP Kit(Rabbit) (sp-0023) instructionsand DAB staining.
|
| 1、抗体溶解方法 | |
| 2、抗体修复方式 | |
| 3、常用试剂的配制 | |
| 4、免疫组化操作步骤 | |
| 5、免疫组化问题解答 | |
| 6、Western Blotting 操作步骤 | |
| 7、Western Blotting 问题解答 | |
| 8、关于肽链的设计 | |
| 9、多肽的溶解与保存 | |
| 10、酶标抗体效价测定程序 | |
